CN107406485A - 用于治疗癌症的肽 - Google Patents

用于治疗癌症的肽 Download PDF

Info

Publication number
CN107406485A
CN107406485A CN201580054152.2A CN201580054152A CN107406485A CN 107406485 A CN107406485 A CN 107406485A CN 201580054152 A CN201580054152 A CN 201580054152A CN 107406485 A CN107406485 A CN 107406485A
Authority
CN
China
Prior art keywords
pro
arg
trp
nap
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201580054152.2A
Other languages
English (en)
Chinese (zh)
Inventor
希尔马·M·瓦雷纽斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CN107406485A publication Critical patent/CN107406485A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1077—Pentosyltransferases (2.4.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/02—Pentosyltransferases (2.4.2)
    • C12Y204/0203—NAD+ ADP-ribosyltransferase (2.4.2.30), i.e. tankyrase or poly(ADP-ribose) polymerase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
CN201580054152.2A 2014-08-06 2015-08-05 用于治疗癌症的肽 Pending CN107406485A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1413942.2 2014-08-06
GB1413942.2A GB2530479A (en) 2014-08-06 2014-08-06 Peptides useful for treating cancer
PCT/EP2015/068056 WO2016020437A1 (en) 2014-08-06 2015-08-05 Peptides useful for treating cancer

Publications (1)

Publication Number Publication Date
CN107406485A true CN107406485A (zh) 2017-11-28

Family

ID=51587828

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580054152.2A Pending CN107406485A (zh) 2014-08-06 2015-08-05 用于治疗癌症的肽

Country Status (9)

Country Link
US (1) US20170313746A1 (cg-RX-API-DMAC10.html)
EP (1) EP3177716A1 (cg-RX-API-DMAC10.html)
JP (1) JP2017529386A (cg-RX-API-DMAC10.html)
CN (1) CN107406485A (cg-RX-API-DMAC10.html)
AU (1) AU2015299032A1 (cg-RX-API-DMAC10.html)
CA (1) CA2960070A1 (cg-RX-API-DMAC10.html)
GB (1) GB2530479A (cg-RX-API-DMAC10.html)
RU (1) RU2017106945A (cg-RX-API-DMAC10.html)
WO (1) WO2016020437A1 (cg-RX-API-DMAC10.html)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109790523A (zh) * 2016-02-10 2019-05-21 希尔马·M·瓦雷纽斯 组合物及其用途
WO2022222261A1 (zh) * 2021-04-21 2022-10-27 苏州大学 一种己糖激酶2抑制剂的筛选方法和小分子化合物在制备抗肿瘤药物中的应用

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017066454A2 (en) 2015-10-14 2017-04-20 X-Therma, Inc. Compositions and methods for reducing ice crystal formation
GB2582571B (en) 2019-03-25 2024-02-28 Syntherix Ltd Peptides and use thereof
GB2628421A (en) 2023-03-24 2024-09-25 Syntherix Ltd Peptides and uses thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002045720A1 (en) * 2000-12-04 2002-06-13 Sloan-Kettering Institute For Cancer Research Treatment of cancer by reduction of intracellular energy and pyrimidines
WO2009112536A1 (en) * 2008-03-11 2009-09-17 Theryte Limited Treating cancer
WO2014004935A2 (en) * 2012-06-27 2014-01-03 Siscapa Assay Technologies, Inc. Multipurpose mass spectrometric assay panels for peptides
WO2014055836A2 (en) * 2012-10-04 2014-04-10 Research Development Foundation Serine protease molecules and therapies

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002316419A1 (en) * 2001-07-05 2003-01-21 Yale University Improvement of viral uptake into cells and tissues
US7439031B2 (en) * 2003-12-15 2008-10-21 The Trustees Of The University Of Pennsylvania Method of identifying compounds that induce cell death by necrosis
WO2014053879A1 (en) * 2012-10-04 2014-04-10 Centre National De La Recherche Scientifique Cell penetrating peptides for intracellular delivery of molecules

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002045720A1 (en) * 2000-12-04 2002-06-13 Sloan-Kettering Institute For Cancer Research Treatment of cancer by reduction of intracellular energy and pyrimidines
WO2009112536A1 (en) * 2008-03-11 2009-09-17 Theryte Limited Treating cancer
WO2014004935A2 (en) * 2012-06-27 2014-01-03 Siscapa Assay Technologies, Inc. Multipurpose mass spectrometric assay panels for peptides
WO2014055836A2 (en) * 2012-10-04 2014-04-10 Research Development Foundation Serine protease molecules and therapies

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
AMIR NASROLAHI SHIRAZI等: "Efficient Delivery of Cell Impermeable Phosphopeptides by a Cyclic Peptide Amphiphile Containing Tryptophan and Arginine", 《MOL PHARM》 *
D DEROSSI 等: "Trojan Peptides: The Penetratin System for Intracellular Delivery", 《TRENDS CELL BIOL》 *
HILMAR M WARENIUS等: "Selective Anticancer Activity of a Hexapeptide With Sequence Homology to a Non-Kinase Domain of Cyclin Dependent Kinase 4", 《MOL CANCER》 *
KEITH A MENEAR等: "4-[3-(4-Cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: A Novel Bioavailable Inhibitor of Poly(ADP-ribose) Polymerase-1", 《J MED CHEM》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109790523A (zh) * 2016-02-10 2019-05-21 希尔马·M·瓦雷纽斯 组合物及其用途
WO2022222261A1 (zh) * 2021-04-21 2022-10-27 苏州大学 一种己糖激酶2抑制剂的筛选方法和小分子化合物在制备抗肿瘤药物中的应用

Also Published As

Publication number Publication date
GB2530479A (en) 2016-03-30
RU2017106945A (ru) 2018-09-06
WO2016020437A1 (en) 2016-02-11
US20170313746A1 (en) 2017-11-02
AU2015299032A1 (en) 2017-03-23
JP2017529386A (ja) 2017-10-05
GB201413942D0 (en) 2014-09-17
EP3177716A1 (en) 2017-06-14
RU2017106945A3 (cg-RX-API-DMAC10.html) 2019-03-28
CA2960070A1 (en) 2016-02-11

Similar Documents

Publication Publication Date Title
Kooij et al. Small-molecule activity-based probe for monitoring ubiquitin C-terminal hydrolase L1 (UCHL1) activity in live cells and zebrafish embryos
Humphreys et al. The role of E3 ubiquitin ligases in the development and progression of glioblastoma
DeVine et al. Targeting the ubiquitin-mediated proteasome degradation of p53 for cancer therapy
Krämer et al. SIAH proteins: critical roles in leukemogenesis
Scholz et al. Targeting the ubiquitin system in glioblastoma
Li et al. USP32 deubiquitinase: cellular functions, regulatory mechanisms, and potential as a cancer therapy target
JP2015536990A (ja) Ｍａｌｔ１の低分子阻害剤
US20170313746A1 (en) Peptides Useful For Treating Cancer
JP2015529665A (ja) Ｍｔｈ１阻害剤としてのアミノヘテロアリール化合物
Blaquiere et al. Medicinal chemistry of inhibiting RING-type E3 ubiquitin ligases
Cui et al. Small molecule inhibitors targeting the “undruggable” survivin: the past, present, and future from a medicinal chemist’s perspective
Velasco et al. An N-terminal SIAH-interacting motif regulates the stability of the ubiquitin specific protease (USP)-19
WO2007088099A2 (en) Compounds for the treatment of ischemia and neurodegeneration
Chaturvedi et al. Recapitulating the potential contribution of protein S-palmitoylation in cancer
Bano et al. A review on cullin neddylation and strategies to identify its inhibitors for cancer therapy
US12570697B2 (en) Cyclic peptide useful in the treatment of cancer
Pérez‐Payá et al. Molecules that modulate Apaf‐1 activity
US20190046600A1 (en) Compositions and uses thereof
US11071727B2 (en) Therapeutic targeting of proteolytic cleavage of the mixed lineage leukemia gene product (MLL1) by taspase1 using kinase inhibitors
US20160138026A1 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF VprBP-RELATED CANCERS
WO2023175615A1 (en) Arts mimetic componds and combinations thereof for treating high-risk neuroblastoma
ES2396115T3 (es) Uso de inhibidores de la degradación de p27, en particular argirina y derivados de la misma, para el tratamiento del cáncer
Zhao et al. Sentrin/SUMO-specific protease 1 contributes to drug resistance in melanoma by mediating the deSUMOylation of Yes-associated protein
Kraft Synthesis and Characterization of Histone Deacetylase (HDAC) Inhibitors and PROTACs
Benítez García Identification and Preclinical Evaluation of Asenapine Maleate as a Direct Survivin Inhibitor for Lung Cancer Therapy and Sensitization to Proapoptotic Treatments

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20171128

WD01 Invention patent application deemed withdrawn after publication